ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3).
Markt SC., Shui IM., Unger RH., Urun Y., Berg CD., Black A., Brennan P., Bueno-de-Mesquita HB., Gapstur SM., Giovannucci E., Haiman C., Henderson B., Hoover RN., Hunter DJ., Key TJ., Khaw KT., Canzian F., Larranga N., Le Marchand L., Ma J., Naccarati A., Siddiq A., Stampfer MJ., Stattin P., Stevens VL., Stram DO., Tjønneland A., Travis RC., Trichopoulos D., Ziegler RG., Lindstrom S., Kraft P., Mucci LA., Choueiri TK., Wilson KM.
BACKGROUND: ABO blood group has been associated with risk of cancers of the pancreas, stomach, ovary, kidney, and skin, but has not been evaluated in relation to risk of aggressive prostate cancer. METHODS: We used three single nucleotide polymorphisms (SNPs) (rs8176746, rs505922, and rs8176704) to determine ABO genotype in 2,774 aggressive prostate cancer cases and 4,443 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3). Unconditional logistic regression was used to calculate age and study-adjusted odds ratios and 95% confidence intervals for the association between blood type, genotype, and risk of aggressive prostate cancer (Gleason score ≥8 or locally advanced/metastatic disease (stage T3/T4/N1/M1). RESULTS: We found no association between ABO blood type and risk of aggressive prostate cancer (Type A: OR = 0.97, 95%CI = 0.87-1.08; Type B: OR = 0.92, 95%CI =n0.77-1.09; Type AB: OR = 1.25, 95%CI = 0.98-1.59, compared to Type O, respectively). Similarly, there was no association between "dose" of A or B alleles and aggressive prostate cancer risk. CONCLUSIONS: ABO blood type was not associated with risk of aggressive prostate cancer.